Volume : 09, Issue : 04, April – 2022
Title:
42.CURATIVE TREATMENT OF PANCREATIC CANCER: A REVIEW
Authors :
Shantanu Choubey, Samkit Jain, Sharad Singh Dangi, Shubham Awadhiya, Sharad Kumar Kurmi, Ms. Megha Shrivastava*
Abstract :
Pancreatic cancer is the second most common digestive cancer in the United States, with roughly 44,000 new cases diagnosed each year. It is the sixth most common cancer in Europe, accounting for 2.8 percent of male malignancies and 3.2 percent of female cancers. It is the fifth biggest cause of cancer-related death, with a five-year survival rate of fewer than 10%. Nonetheless, the most important factors of ultimate prognosis are tumour biology and adjuvant therapy. As a result, many surgeons believe that less invasive treatments (such as the pylorus-preserving pancreatoduodenectomy), which are associated with a shorter surgical time, less blood loss, and an equally long but higher quality of survival, are the best option. The current research examines cost-effectiveness studies on pancreatic cancer treatment that have been published.
Key words: Pancreatic cancer, Treatment, Epidemiology Symptom
Cite This Article:
Please cite this article in press Megha Shrivastava et al, Curative Treatment Of Pancreatic Cancer: A Review., Indo Am. J. P. Sci, 2022; 09(04).,
Number of Downloads : 10
References:
1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
2. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267.
3. Kamisawa T, Isawa T, Koike M, et al. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas 1995; 11: 345–49.
4. Sah RP, Nagpal SJS, Mukhopadhyay D, et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10: 423–33.
5. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2014. Ann Oncol 2014; 25: 1650–56.
6. Hruban RH, Boff etta P, Hiraoka N, et al. Ductal adenocarcinoma of the pancreas. In: Hruban RH, Hiraoka N, Iacobuzio-Donahue C, et al. WHO classifi cation of tumours of the digestive system. In: Bosman FTJ, Lakhani SR, Ohgaki H, eds. WHO classifi cation of tumours, 4th edn. Lyon: International Agency for Research on Cancer, 2010: 281–91.
7. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64: 2634–38.
8. Fukushima N, Hruban RH, Kato Y, et al. Ductal adenocarcinoma variants and mixed neoplasms of the pancreas. In: Fukushima N, Klimstra DS, Kloppel G, et al. WHO classifi cation of tumours of the digestive system. In: Bosman FTJ, Lakhani SR, Ohgaki H, eds. WHO classifi cation of tumours. 4th edn. Lyon: International Agency for Research on Cancer, 2010: 292–95.
9. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 2007; 142: 767–723, discussion 773–74.
10. Cosci F, Fava GA, Sonino N. Mood and anxiety disorders as early manifestations of medical illness: a systematic review. Psychother Psychosom 2015; 84: 22–29.
11. Grahm AL, Andrén-Sandberg A. Prospective evaluation of pain in exocrine pancreatic cancer. Digestion 1997; 58: 542–49.
12. Chan A, Prassas I, Dimitromanolakis A, et al. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res 2014; 20: 5787–95.
13. Conrad C, Fernández-Del Castillo C. Preoperative evaluation and management of the pancreatic head mass. J Surg Oncol 2013; 107: 23–32.
14. Fan Z, Li Y, Yan K, et al. Application of contrast-enhanced ultrasound in the diagnosis of solid pancreatic lesions–a comparison of conventional ultrasound and contrast-enhanced CT. Eur J Radiol 2013; 82: 1385–90.
15. Kalser, M. H. & Ellenberg, S. S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120, 899–903 (1985).
16. Ghaferi, A. A., Birkmeyer, J. D. & Dimick, J. B. Variation in hospital mortality associated with inpatient surgery. N. Engl. J. Med. 361, 1368–1375 (2009).
17. Ohuchida, K. et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor–stromal interactions. Cancer Res. 64, 3215–3222 (2004).
18. Rougier, P. et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first- line treatment with gemcitabine for metastatic pancreatic cancer. Eur. J. Cancer 49, 2633–2642 (2013).
19. Johnson, D. B. et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 19, 616–622 (2014).
20. Safran, H. et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 22, 706–712 (2004).
21. Takebe, N., McShane, L. & Conley, B. Exceptional responders—discovering predictive biomarkers. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/ nrclinonc.2015.19 (2015).
22. Drummond, D. C. et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 66, 3271–3277 (2006).
23. Yoo, C. et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine- refractory advanced pancreatic cancer. Br. J. Cancer 101, 1658–1663 (2009).
24. Chandra, A. et al. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat. Cell Biol. 14, 148–158 (2012).
25. Laheru, D. et al. Integrated preclinical and clinical development of S-trans, trans- farnesylthiosalicylic acid (FTS, salirasib) in pancreatic cancer. Invest. New Drugs 30, 2391–2399 (2012).
26. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).
27. Zorde Khvalevsky, E. et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20723–20728 (2013).
28. Verstovsek, S. et al. A double-blind, placebo- controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799–807 (2012).
29. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/ NCT01506973 (2013).
30. Wolpin, B. M. et al. Oral mTOR inhibitor everolimus in patients with gemcitabine- refractory metastatic pancreatic cancer. J. Clin. Oncol. 27, 193–198 (2009).
31. Von Hoff, D. D. et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164–1172 (2009).
32. Madden, J. I. Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. Infinity Pharmaceuticals.
33. Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735–747 (2014).
34. Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418–429 (2012).
35. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/ NCT01959139 (2014).
36. Wormann, S. M., Diakopoulos, K. N., Lesina, M. & Algul, H. The immune network in pancreatic cancer development and progression. Oncogene 33, 2956–2967 (2014).
37. Melero, I., Grimaldi, A. M., Perez-Gracia, J. L. & Ascierto, P. A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res. 19, 997–1008 (2013).
38. Nomi, T. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13, 2151–2157 (2007).
39. Grupp, S. A. et al. Chimeric antigen receptor- modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).
40. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/ NCT01897415 (2014).
41. Mellor, A. L. et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171, 1652–1655 (2003).
42. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/ NCT02077881 (2015).